Steady-state plasma and intrapulmonary concentrations of levofloxacin and ciprofloxacin in healthy adult subjects

Chest

Volumn 119, Issue 4, 2001, Pages 1114-1122

  Gotfried, Mark H ^a   Danziger, Larry H ^b   Rodvold, Keith A ^b  

^a UNIVERSITY OF ARIZONA   (United States)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

Ciprofloxacin; Fluoroquinolone; Levofloxacin; Penetration; Pharmacokinetics; Respiratory tract infection

Indexed keywords

CIPROFLOXACIN; LEVOFLOXACIN;

ABDOMINAL CRAMP; ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DROWSINESS; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG PENETRATION; FEMALE; HUMAN; INSOMNIA; LUNG ALVEOLUS EPITHELIUM; LUNG ALVEOLUS MACROPHAGE; MALE; NAUSEA; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STOMACH DISEASE; VERTIGO;

EID: 0034917313     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.119.4.1114     Document Type: Article

References (49)

1. Community-acquired pneumonia in adults: Guidelines for management
2. Efficacy and tolerability of twice-daily ciprofloxacin 750 mg in the treatment of patients with acute exacerbations of chronic bronchitis and pneumonia
3. Safety and efficacy of oral levofloxacin versus cefuroxime axetil in acute bacterial exacerbations of chronic bronchitis
4. A multicenter, randomized study comparing the efficacy and safety of intravenous and/or oral levofloxacin versus ceftriaxone and/or cefuroxime axetil in treatment of adults with community-acquired pneumonia
5. Once a day levofloxacin in the treatment of mild to moderate and severe community-acquired pneumonia in adults
6. Multicenter, randomized study comparing efficacy and safety of oral levofloxacin and cefaclor in treatment of acute bacterial exacerbations of chronic bronchitis
7. Levofloxacin versus cefuroxime axetil in the treatment of acute exacerbation of chronic bronchitis: Results of a randomized, double-blind study
8. Fluoroquinolone toxicity profile: A review focusing on newer agents
9. Clinical safety profile of newer fluoroquinolones
10. Intrapulmonary concentrations of antimicrobial agents
11. Concentrations of levofloxacin (HR 355) in the respiratory tract after a single oral dose in patients undergoing fiber-optic bronchoscopy
12. The distribution of ciprofloxacin and its metabolites in human plasma, pulmonary and bronchial tissues
13. Penetration of ciprofloxacin into bronchial secretions
14. Ciprofloxacin concentrations in lung tissue after a single 400 mg intravenous dose
15. The penetration of ciprofloxacin into bronchial mucosa, lung parenchyma, and pleural tissue after intravenous administration
16. Steady-state pharmacokinetics of ciprofloxacin in plasma from patients with nosocomial pneumonia: Penetration of the bronchial mucosa
17. Lung tissue concentrations of ciprofloxacin after intravenous administration in patients
18. Ciprofloxacin: Multiple-dose pharmacokinetic and clinical results in patients with hypercrinic bronchopulmonary diseases
19. Evaluation of the penetration of ciprofloxacin and amoxycillin into the bronchial mucosa
20. Ciprofloxacin penetration into lungs
21. Concentration of ciprofloxacin in human serum, lung and pleural tissues and fluids during and after lung surgery
22. Penetration of levofloxacin into lung tissues after oral administration to subjects undergoing lung biopsy or lobectomy
23. Brief report: Respiratory tract penetration of ciprofloxacin
24. Penetration of ciprofloxacin and metabolites into human lung, bronchial and pleural tissue after 250 and 500 mg oral ciprofloxacin
25. Penetration of pefloxacin and ciprofloxacin into lung tissue
26. Penetration of ciprofloxacin into human lung tissue after intravenous injection
27. Reproducibility of the measurement of ciprofloxacin concentration in bronchial mucosa
28. Pulmonary disposition of antimicrobial agents: Methodologic considerations
29. Pulmonary disposition of antimicrobial agents: Observations and clinical relevance
30. Concentrations of antimicrobials in the pulmonary alveolar epithelial lining
31. Interpretation of pharmacologic data in respiratory tract infections
32. Intrapulmonary steady-state concentrations of clarithromycin and azithromycin in healthy adult volunteers
33. The significance of serum vs tissue levels of antibiotics in the treatment of penicillin-resistant Streptococcus pneumoniae and community-acquired pneumonia: Are we looking in the wrong place?
34. Comparative bronchoalveolar concentrations of ciprofloxacin and lomefloxacin after oral administration
35. Single-dose intrapulmonary pharmacokinetics of azithromycin, clarithromycin, ciprofloxacin, and cefuroxime in volunteer subjects
36. Penetration of sparfloxacin and ciprofloxacin into alveolar macrophages, epithelial lining fluid, and polymorphonuclear leukocytes
37. Metropolitan height weight tables
38. Azithromycin concentrations at the sites of pulmonary infection
39. Comparison of bronchopulmonary pharmacokinetics of clarithromycin and azithromycin
40. High-performance liquid chromatographic procedures for the determination of temafloxacin in biological matrices
41. Guidelines for the initial management of adults with community-acquired pneumonia: Diagnosis, assessment of severity, and initial antimicrobial therapy
42. Comparative penetration of selected fluoroquinolones into respiratory tract fluids and tissues
43. Comparative pharmacokinetic disposition of fluoroquinolones in the lung
44. Pharmacokinetic/pharmacodynamic parameters: Rationale for antibacterial dosing of mice and men
45. Pharmacodynamics of levofloxacin: A new paradigm of early clinical trials
46. Surveillance of antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the United States in 1996-1997 respiratory season: The Laboratory Investigator Group
47. Resistance surveillance of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis isolated in the United States, 1997-1998
48. Double-blind evaluation of the safety and pharmacokinetics of multiple oral once-daily 750-mg and 1-gram doses of levofloxacin in healthy volunteers
49. Pharmacokinetics and safety of high-dose and extended-interval regimens of levofloxacin in human immunodeficiency virus-infected patients